Differentiated thyroid cancer

Seminars in Oncology

Volumn 37, Issue 6, 2010, Pages 557-566

  Burns, William R ^a   Zeiger, Martha A ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; FLUORODEOXYGLUCOSE F 18; IODINE 131; LENALIDOMIDE; MOTESANIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; SORAFENIB; SUNITINIB; THALIDOMIDE; THYROTROPIN; THYROXINE; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CARDIOTOXICITY; CERVICAL LYMPH NODE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG INDICATION; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HYPOTHYROIDISM; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL TECHNOLOGY; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NECK DISSECTION; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SKIN TOXICITY; SUBTOTAL THYROIDECTOMY; SURGICAL TECHNIQUE; SURVIVAL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE;

HUMANS; IODINE RADIOISOTOPES; MOLECULAR TARGETED THERAPY; NECK DISSECTION; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 78650238121     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.10.008     Document Type: Article

References (74)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. L. Davies, and H.G. Welch Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295 2006 2164 2167
3. D.S. Cooper, G.M. Doherty, and B.R. Haugen Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 2009 1167 1214
4. M.A. Zeiger, and A.P. Dackiw Follicular thyroid lesions, elements that affect both diagnosis and prognosis J Surg Oncol 89 2005 108 113
5. I.D. Hay, C.S. Grant, W.F. Taylor, and W.M. McConahey Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system Surgery 102 1987 1088 1095
6. B. Cady, and R. Rossi An expanded view of risk-group definition in differentiated thyroid carcinoma Surgery 104 1988 947 953
7. I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, and C.S. Grant Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 Surgery 114 1993 1050 1057
8. S.B. Edge American Joint Committee on Cancer Thyroid 87-96 S.B. Edge, American Joint Committee on Cancer, editors AJCC cancer staging manual 7th ed. 2010 Springer New York
9. S.I. Sherman, J.D. Brierley, and M. Sperling Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome National Thyroid Cancer Treatment Cooperative Study Registry Group Cancer 83 1998 1012 1021
10. Y. Ito, T. Higashiyama, and Y. Takamura Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection World J Surg 31 2007 2085 2091
11. M.H. Chew, G. Chan, and M.M. Siddiqui Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003 World J Surg 32 2008 386 394
12. L.J. DeGroot, E.L. Kaplan, M. McCormick, and F.H. Straus Natural history, treatment, and course of papillary thyroid carcinoma J Clin Endocrinol Metab 71 1990 414 424
13. E.Y. Soh, and O.H. Clark Surgical considerations and approach to thyroid cancer Endocrinol Metab Clin North Am 25 1996 115 139
14. K.Y. Bilimoria, D.J. Bentrem, and C.Y. Ko Extent of surgery affects survival for papillary thyroid cancer Ann Surg 246 2007 375 381
15. E.L. Mazzaferri, and R.L. Young Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients Am J Med 70 1981 511 518
16. N.A. Samaan, P.N. Schultz, and R.C. Hickey The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients J Clin Endocrinol Metab 75 1992 714 720
17. E.L. Mazzaferri, and S.M. Jhiang Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer Am J Med 97 1994 418 428
18. I.D. Hay, G.B. Thompson, and C.S. Grant Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients World J Surg 26 2002 879 885
19. R. Katoh, J. Sasaki, H. Kurihara, K. Suzuki, Y. Iida, and A. Kawaoi Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma A clinicopathologic study of 105 consecutive patients Cancer 70 1992 1585 1590
20. F. Pacini, R. Elisei, and M. Capezzone Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low and high-risk patients Thyroid 11 2001 877 881
21. E.S. Kim, T.Y. Kim, and J.M. Koh Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation Clin Endocrinol (Oxf) 61 2004 145 148
22. H.R. Tollefsen, and J.J. Decosse Papillary carcinoma of the thyroid Recurrence in the thyroid gland after initial surgical treatment Am J Surg 106 1963 728 734
23. J.L. Pasieka, N.W. Thompson, M.K. McLeod, R.E. Burney, and M. Macha The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy World J Surg 16 1992 711 716
24. S.K. Grebe, and I.D. Hay Thyroid cancer nodal metastases: biologic significance and therapeutic considerations Surg Oncol Clin North Am 5 1996 43 63
25. S. Noguchi, A. Noguchi, and N. Murakami Papillary carcinoma of the thyroid I. Developing pattern of metastasis Cancer 26 1970 1053 1060
26. F. Arturi, D. Russo, and D. Giuffrida Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes J Clin Endocrinol Metab 82 1997 1638 1641
27. V. Zaydfudim, I.D. Feurer, M.R. Griffin, and J.E. Phay The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma Surgery 144 2008 1070 1077
28. C.I. Lundgren, P. Hall, P.W. Dickman, and J. Zedenius Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study Cancer 106 2006 524 531
29. Y.D. Podnos, D. Smith, L.D. Wagman, and J.D. Ellenhorn The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer Am Surg 71 2005 731 734
30. J.D. Brierley, T. Panzarella, R.W. Tsang, M.K. Gospodarowicz, and B. O'Sullivan A comparison of different staging systems predictability of patient outcome Thyroid carcinoma as an example Cancer 79 1997 2414 2423
31. S.E. Carty, D.S. Cooper, and G.M. Doherty Consensus statement on the terminology and classification of central neck dissection for thyroid cancer Thyroid 19 2009 1153 1158
32. M.L. White, P.G. Gauger, and G.M. Doherty Central lymph node dissection in differentiated thyroid cancer World J Surg 31 2007 895 904
33. E.J. Chisholm, E. Kulinskaya, and N.S. Tolley Systematic review and metaanalysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone Laryngoscope 119 2009 1135 1139
34. Y. Ito, T. Jikuzono, and T. Higashiyama Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe World J Surg 30 2006 1821 1828
35. M.A. Kouvaraki, S.E. Shapiro, and B.D. Fornage Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer Surgery 134 2003 946 954
36. J.F. Moley, and M.K. DeBenedetti Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection Ann Surg 229 1999 880 887
37. G.F. Scheumann, O. Gimm, G. Wegener, H. Hundeshagen, and H. Dralle Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer World J Surg 18 1994 559 567
38. L.E. Tisell, B. Nilsson, and J. Molne Improved survival of patients with papillary thyroid cancer after surgical microdissection World J Surg 20 1996 854 859
39. E. Gemsenjager, A. Perren, B. Seifert, G. Schuler, I. Schweizer, and P.U. Heitz Lymph node surgery in papillary thyroid carcinoma J Am Coll Surg 197 2003 182 190
40. Y. Ito, C. Tomoda, and T. Uruno Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid World J Surg 28 2004 498 501
41. M.E. Kupferman, M. Patterson, S.J. Mandel, V. LiVolsi, and R.S. Weber Patterns of lateral neck metastasis in papillary thyroid carcinoma Arch Otolaryngol Head Neck Surg 130 2004 857 860
42. Y. Yanir, and I. Doweck Regional metastases in well-differentiated thyroid carcinoma: pattern of spread Laryngoscope 118 2008 433 436
43. T. Farrag, F. Lin, N. Brownlee, M. Kim, S. Sheth, and R.P. Tufano Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels World J Surg 33 2009 1680 1683
44. I. Yuce, S. Cagli, A. Bayram, F. Karasu, and E. Guney Regional metastatic pattern of papillary thyroid carcinoma Eur Arch Otorhinolaryngol 267 2010 437 441
45. N.R. Caron, Y.Y. Tan, and J.B. Ogilvie Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary? World J Surg 30 2006 833 840
46. C.F. Eustatia-Rutten, J.W. Smit, and J.A. Romijn Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis Clin Endocrinol (Oxf) 61 2004 61 74
47. G. Dai, O. Levy, and N. Carrasco Cloning and characterization of the thyroid iodide transporter Nature 379 1996 458 460
48. G.C. Rutherford, B. Franc, and A. O'Connor Nuclear medicine in the assessment of differentiated thyroid cancer Clin Radiol 63 2008 453 463
49. T. Taylor, B. Specker, and J. Robbins Outcome after treatment of high risk papillary and non-Hurthle-cell follicular thyroid carcinoma Ann Intern Med 129 1998 622 627
50. E.L. Mazzaferri, and R.T. Kloos Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer J Clin Endocrinol Metab 86 2001 1447 1463
51. T.S. Jung, T.Y. Kim, and K.W. Kim Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma Endocr J 54 2007 265 274
52. J. Jonklaas, N.J. Sarlis, and D. Litofsky Outcomes of patients with differentiated thyroid carcinoma following initial therapy Thyroid 16 2006 1229 1242
53. A.M. Sawka, J.D. Brierley, and R.W. Tsang An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer Endocrinol Metab Clin North Am 37 2008 457 480
54. T.J. Stahl, and B. Shapiro Use of human thyrotropin radioimmunoassay in the management of patients with thyroid carcinoma J Nucl Med 14 1973 900 902
55. J.M. Goldman, B.R. Line, R.L. Aamodt, and J. Robbins Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer J Clin Endocrinol Metab 50 1980 734 739
56. F. Pacini, P.W. Ladenson, and M. Schlumberger Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study J Clin Endocrinol Metab 91 2006 926 932
57. R.M. Tuttle, M. Brokhin, and G. Omry Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal J Nucl Med 49 2008 764 770
58. S.A. Terezakis, K.S. Lee, and R.A. Ghossein Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience Int J Radiat Oncol Biol Phys 73 2009 795 801
59. S.I. Sherman Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers J Clin Endocrinol Metab 94 2009 1493 1499
60. V. Gupta-Abramson, A.B. Troxel, and A. Nellore Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 2008 4714 4719
61. R.T. Kloos, M.D. Ringel, and M.V. Knopp Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 27 2009 1675 1684
62. H. Hoftijzer, K.A. Heemstra, and H. Morreau Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma Eur J Endocrinol 161 2009 923 931
63. S.I. Sherman, L.J. Wirth, and J.P. Droz Motesanib diphosphate in progressive differentiated thyroid cancer N Engl J Med 359 2008 31 42
64. E.E. Cohen, B.M. Needles, and K.J. Cullen Phase 2 study of sunitinib in refractory thyroid cancer [abstract] J Clin Oncol (Meeting abstracts) 26 2008 6025
65. A. Ravaud, C. de la Fouchardire, and F. Courbon Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial [abstract] J Clin Oncol (Meeting abstracts) 26 2008 6058
66. E.E. Cohen, L.S. Rosen, and E.E. Vokes Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708 4713
67. K.B. Ain, C. Lee, and K.D. Williams Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas Thyroid 17 2007 663 670
68. K.B. Ain, C. Lee, K.M. Holbrook, J.M. Dziba, and K.D. Williams Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodineunresponsive thyroid carcinomas: preliminary results [abstract] J Clin Oncol (Meeting abstracts) 26 2008 6027
69. 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy J Clin Endocrinol Metab 91 2006 60 63
70. R.M. Tuttle, and R. Leboeuf Follow up approaches in thyroid cancer: a risk adapted paradigm Endocrinol Metab Clin North Am 37 2008 419 435 (Pubitemid 351698090)
71. F. Pacini, M. Capezzone, R. Elisei, C. Ceccarelli, D. Taddei, and A. Pinchera Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment J Clin Endocrinol Metab 87 2002 1499 1501
72. 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer Clin Imaging 32 2008 32 37
73. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer J Clin Endocrinol Metab 94 2009 1310 1316
74. 18F]fluoro-2-deoxy-D-glucose positron emission tomography scanning J Clin Endocrinol Metab 91 2006 498 505